Global Health

Audio Journal of Global Health Issues: Tipranavir Brings Hope for HIV-1 Patients Resistant to Standard Antiretorviral Therapy

Charles Hicks

CHARLES HICKS, Associate Professor Medicine, Duke University, Durham

REFERENCE: Lancet 2006; 368: 466-75
Results with a new antiretroviral agent, tipranavir, tested among patients who were resistant to standard therapies have been published in The Lancet. Charles Hicks of Duke University in North Carolina told Sarah Maxwell about the treatment responses they’ve reported and the potential role of this agent for treating late stages of HIV infection.

Similar Interviews

  • Once-And-For-All TB Assay Brings Cheap, Sensitive, Specific, Seven-Day Diagnosis and Drug-Susceptibility Testing
  • DAVID MOORE, Imperial College, London and Lima REFERENCE: N Engl J Med 355: 1539-50 A new test for TB, trialled in Peru,

  • Non-Perfect HIV Vaccine Could Still Have Major Benefits
  • ANTHONY FAUCI, National Institutes of Health, Bethesda REFERENCE: N Engl J Med 2007;356:2073-81 Is there any hope for an HIV vaccine? According

  • Audio Journal of Oncology 14.2, March 2006
  • Reporting from: American Society of Hematology Meeting, Atlanta, 10-13 December 2005 In this edition: It is not necessary to use rituximab along with

    Post a comment

    Subscribe to Audio Medica Podcast